EcoDrugPlus

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Delta

Ensembl ID : ENSPLAG00000020276
Gene Symbol: PIK3CD
3 Cross references
209 Possible Orthologues:

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Gamma

Ensembl ID : ENSPLAG00000012648
Gene Symbol: PIK3CG
3 Cross references
213 Possible Orthologues:

Phosphodiesterase 10a

Ensembl ID : ENSPLAG00000023708
Gene Symbol: PDE10A
3 Cross references
205 Possible Orthologues:

Phosphodiesterase 3a

Ensembl ID : ENSPLAG00000002891
Gene Symbol: PDE3A
3 Cross references
195 Possible Orthologues:

Phosphodiesterase 3a

Ensembl ID : ENSPLAG00000021334
Gene Symbol: PDE3A
3 Cross references
215 Possible Orthologues:

Phosphodiesterase 3b

Ensembl ID : ENSPLAG00000008748
Gene Symbol: PDE3B
3 Cross references
217 Possible Orthologues:

Phosphodiesterase 4a

Ensembl ID : ENSPLAG00000001575
Gene Symbol: PDE4A
3 Cross references
201 Possible Orthologues:

Phosphodiesterase 4b

Ensembl ID : ENSPLAG00000023010
Gene Symbol: PDE4B
3 Cross references
228 Possible Orthologues:

Phosphodiesterase 4d

Ensembl ID : ENSPLAG00000019318
Gene Symbol: PDE4D
3 Cross references
235 Possible Orthologues:

Phosphodiesterase 7a

Ensembl ID : ENSPLAG00000006983
Gene Symbol: PDE7A
3 Cross references
227 Possible Orthologues:

Phosphodiesterase 7b

Ensembl ID : ENSPLAG00000005847
Gene Symbol: PDE7B
4 Cross references
189 Possible Orthologues:

Phosphoinositide 3-Kinase Regulatory Subunit 5-Like

Ensembl ID : ENSPLAG00000000710
Gene Symbol: LOC106963936
2 Cross references
185 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).